AI helps find promising therapeutic target for rare salivary gland cancer
Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...
Pharmabiz2d
Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor
Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...
Global Times4d
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...